Results 11 to 20 of about 12,381 (205)
Differentiated T Lymphocytes and Cancer Cell Mitochondrial Metabolism to Enhance Radioimmunotherapy by a Biomimetic Nanozyme System. [PDF]
Adv Sci (Weinh)T cell membrane‐coated MgCO3/Fe‐CD nanozyme loaded with TEPP‐46 (TFMP) enhances breast cancer radioimmunotherapy by reprogramming mitochondrial metabolism in T cells and tumors. It targets PD‐L1, converts H2O2 into ROS, neutralizes acidity, and releases Mg2⁺/TEPP‐46 to boost T cell activation.
Zhang H +7 more
europepmc +2 more sources
Cell Death Discovery, 2022 Radiation resistance and unsatisfactory efficacy of radioimmunotherapy are important barriers to non-small cell lung cancer (NSCLC) treatment. The impacts of anlotinib on radiation and tumor immune microenvironment (TIME) in NSCLC remain to be resolved ...
Dong Han +5 more
doaj +1 more source
Pretargeted Radioimmunotherapy
International Journal of Radiation Oncology*Biology*Physics, 2006 This brief review covers the concept of pretargeted radioimmunotherapy and summarize the results obtained in preclinical animal models and initial phase I clinical trials. Reagents studied have been a bifunctional antibody prepared by crosslinking Fab' fragments from two antibodies with different specificity, one binding the target antigen expressed on
Ruby F, Meredith, Donald J, Buchsbaum
openaire +4 more sources
Immunostimulatory effects of radioimmunotherapy [PDF]
Journal for ImmunoTherapy of Cancer, 2022 Radiation therapy (RT) is known for its ability to kill cancer cells in an immunogenic manner. Recent preclinical data demonstrate that targeted alpha-particle therapy shares with RT the capacity to elicit immunostimulatory effects, standing out as a promising strategy to circumvent immune checkpoint inhibitor resistance in immunologically ‘cold ...
Constanzo, Julie +2 more
openaire +3 more sources
Immunotherapy and Radioimmunotherapy for Desmoplastic Small Round Cell Tumor
Frontiers in Oncology, 2021 Desmoplastic small round cell tumor (DRSCT) is a highly aggressive primitive sarcoma that primarily affects adolescent and young adult males. The 5-year survival rate is 15-30% and few curative treatment options exist.
Madelyn Espinosa-Cotton +1 more
doaj +1 more source
Fate of 177Lu-CHX-A”-DTPA-Rituximab: In vitro Evaluation in Raji Cell Line
Journal of Radiation and Cancer Research, 2023 Context: Radioimmunotherapy is an emerging treatment modality for various types of cancers. While immunotherapy using monoclonal antibodies has shown promising results, particularly in hematological malignancies, a significant number of patients develop ...
Saloni Arun Samant +2 more
doaj +1 more source
Seminars in Radiation Oncology, 2000 Radioimmunotherapy (RIT) is a promising new therapy for the treatment of a variety of malignancies. General principles of RIT are discussed, including important considerations in the selection of monoclonal antibodies (MAb) and radionuclides for RIT.
S J, Knox, R F, Meredith
openaire +2 more sources
Immunoscintigraphy for therapy decision making and follow-up of biological therapies [PDF]
, 2016 With the availability of new biological therapies there is the need of more accurate diagnostic tools to noninvasively assess the presence of their targets.
Auletta, S. +6 more
core +2 more sources
Frontiers in Oncology, 2013 Radioimmunotherapy has demonstrated efficacy with acceptable toxicity leading to approval in non-Hodgkin’s lymphoma, but has been slower to develop for the treatment of advanced solid tumors.
Scott T Tagawa +11 more
doaj +1 more source
Current concepts of 131I therapy in oncology: Indications, methods and follow up [PDF]
Archive of Oncology, 2006 Radioiodine in various forms (as sodium iodide and as the iodinated compounds MIBG, LIPIODOL, et al.) has been used as a therapeutic agent in oncology. Differentiated thyroid carcinoma (DTC) has been successfully treated by 131I therapy.
Mihailović Jasna
doaj +1 more source